Managing Uterine Cancer: Causes, Symptoms, Treatment Options — Overview, Diagnosis & Treatment Options | MyMedicPlus

Uterine cancer — predominantly endometrial carcinoma arising from the endometrium (inner lining) of the uterus — is the most common gynaecological malignancy in developed countries and the fourth most common cancer in women in the United States, with approximately 66,000 new cases and 13,000 deaths per year. Incidence is rising, particularly among obese and elderly women. Two broad pathological categories are recognised. Type I tumours (approximately 80% of cases) are endometrioid adenocarcinomas (Grades 1-3), driven by unopposed oestrogen stimulation, arising on a background of endometrial hyperplasia; these are characteristically oestrogen-receptor and progesterone-receptor positive, associated with obesity, diabetes, nulliparity, and exogenous oestrogen exposure, and carry a generally favourable prognosis when detected early. Type II tumours (approximately 20%) include serous carcinoma, clear cell carcinoma, carcinosarcoma (MMMT), and Grade 3 endometrioid carcinoma; these are biologically aggressive, predominantly TP53-mutated, and are not oestrogen-dependent. The Cancer Genome Atlas (TCGA) molecular classification supersedes histological typing for prognostication and treatment planning, defining four clinically actionable subtypes: POLE-ultramutated (best prognosis), MSI-H/hypermutated, copy number low/TP53 wild-type (intermediate), and copy number high/TP53-aberrant (worst prognosis).

Unopposed oestrogen exposure is the primary aetiological driver of Type I endometrial carcinoma. Obesity is the most important modifiable risk factor: adipose tissue converts androgens to oestrogens via aromatase, creating a hyperoestogenic state; a BMI exceeding 30 confers a 2-4-fold elevated risk, and morbid obesity (BMI above 40) confers a 6-fold elevated risk. Other causes of relative oestrogen excess include nulliparity (absence of progesterone-dominant luteal phase cycles), polycystic ovary syndrome (chronic anovulation), late menopause, diabetes mellitus, and use of exogenous oestrogen without progesterone opposition (oestrogen-only hormone replacement therapy). Tamoxifen — a selective oestrogen receptor modulator used in breast cancer treatment — acts as an oestrogen agonist in the endometrium, increasing endometrial cancer risk by approximately 2-fold; this risk is concentrated in postmenopausal women and requires annual gynaecological surveillance. Hereditary risk: Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) caused by germline mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2) is the most common hereditary endometrial cancer syndrome, conferring a 40-60% lifetime risk; notably, endometrial cancer may be the sentinel Lynch syndrome cancer, diagnosed before colorectal cancer. Type II tumours are driven by TP53 mutations and chromosomal instability, and are not oestrogen-dependent; they arise de novo without a precursor lesion. PTEN tumour suppressor loss, KRAS mutations, and microsatellite instability are common in Type I endometrioid carcinoma.

Postmenopausal vaginal bleeding is the most common, earliest, and most diagnostically valuable symptom of endometrial carcinoma, occurring in over 90% of symptomatic patients and prompting endometrial evaluation. The symptom is so strongly associated with endometrial malignancy that NICE guidelines mandate investigation of all postmenopausal bleeding, regardless of volume or duration; approximately 10% of postmenopausal bleeding is attributable to endometrial carcinoma. Abnormal uterine bleeding in premenopausal women — including intermenstrual bleeding, postcoital bleeding, menorrhagia in the perimenopausal period, or irregular heavy periods — particularly in the setting of obesity, PCOS, or Lynch syndrome, also warrants endometrial evaluation. A watery or blood-tinged vaginal discharge without other explanation is a less common but recognised presentation. Pelvic pain or pressure is an uncommon early symptom but may reflect uterine distension with haematometra (retained blood) or parametrial invasion in advanced disease. Advanced disease may cause anaemia from chronic bleeding, dysuria or urinary frequency from bladder involvement, constipation or rectal bleeding from rectal involvement, or lower limb oedema from lymphatic obstruction. Importantly, incidental detection of endometrial thickness greater than 4 mm on transvaginal ultrasound performed for pelvic pain or other indications in a postmenopausal woman requires endometrial biopsy per standard guidelines.

Endometrial biopsy — using the Pipelle aspiration curette device — is the first-line, office-based diagnostic procedure with approximately 90-95% sensitivity for endometrial carcinoma when adequate tissue is obtained; dilation and curettage (D&C) under anaesthesia is the fallback for insufficient Pipelle samples or ongoing clinical suspicion. Transvaginal ultrasound (TVS) assessment of endometrial thickness is a complementary triage tool: in postmenopausal women, an endometrial thickness of more than 4 mm (or more than 3 mm by some guidelines) warrants biopsy. MRI of the pelvis with gadolinium is the staging investigation of choice, providing highly accurate assessment of myometrial invasion depth (key determinant of adjuvant treatment), cervical stromal extension, and parametrial spread; CT of the chest, abdomen, and pelvis is used for detecting extrauterine disease and peritoneal spread. Sentinel lymph node biopsy (SLN mapping using indocyanine green or technetium-99m) is the preferred nodal staging procedure, replacing full pelvic lymphadenectomy as the standard in most centres. Comprehensive molecular profiling — POLE exonuclease domain mutation testing, MSI/MMR IHC by four-antibody panel (MLH1, MSH2, MSH6, PMS2) or PCR-based MSI assay, TP53 sequencing, and copy number analysis — constitutes the ProMisE or TCGA-surrogate molecular classification now recommended by ESMO and NCCN for all endometrial cancers to guide adjuvant therapy and prognostic counselling. HER2 IHC/FISH testing is indicated for serous endometrial carcinoma, as HER2-positive tumours are candidates for trastuzumab therapy.

Total hysterectomy with bilateral salpingo-oophorectomy (TH-BSO) is the cornerstone surgical treatment for all stages of endometrial carcinoma, achievable by minimally invasive laparoscopic or robotic-assisted techniques for most patients with equivalent oncological and superior perioperative outcomes compared to open laparotomy. Sentinel lymph node mapping with bilateral pelvic SLN biopsy is integrated into staging surgery for all patients except those with low-risk (Grade 1-2 endometrioid, Stage IA without adverse features) disease where nodal assessment may be omitted. Adjuvant therapy is risk-stratified using ESMO/ESGO risk groups and molecular classification. Low-risk (Stage IA Grade 1-2, POLE-mutated, no LVSI): observation. Intermediate risk (Stage IA/IB Grade 1-2, TP53 wild-type, MSS): vaginal vault brachytherapy (VBT, 21 Gy in 3 fractions). High-intermediate risk and Stage II disease: external beam pelvic radiotherapy (EBRT) 45-50 Gy ± VBT. High risk (Stage III, serous, carcinosarcoma, TP53-aberrant): carboplatin plus paclitaxel chemotherapy × 6 cycles ± pelvic EBRT (sequential or concurrent). For advanced/recurrent endometrial cancer: MSI-H/dMMR tumours — pembrolizumab plus lenvatinib (KEYNOTE-775, FDA-approved, HR for OS 0.65) or pembrolizumab monotherapy (high ORR); HER2-positive serous carcinoma — trastuzumab plus carboplatin-paclitaxel (NRG-GY026). MMR-proficient/MSS recurrent disease: pembrolizumab plus lenvatinib (all-comers OS benefit), dostarlimab (dMMR-selected), or platinum-based chemotherapy rechallenge if platinum-sensitive interval exceeds 6 months.

Effective prevention of endometrial cancer is achievable through modification of established hormonal risk factors, which are among the most modifiable of any gynaecological cancer. Weight management is the highest-impact preventive intervention: achieving and maintaining a healthy BMI (under 25) through balanced diet and regular physical activity substantially reduces the chronically elevated oestrogen levels associated with obesity-related endometrial carcinogenesis. Pharmacological prevention with progestins — which antagonise oestrogenic endometrial stimulation — is clinically validated: the levonorgestrel intrauterine system (Mirena IUS) providing local endometrial progestin exposure significantly reduces endometrial cancer risk and is an option for high-risk women preferring intrauterine contraception. Combination oral contraceptive pill use reduces endometrial cancer risk by approximately 50% — the effect persisting for 20 or more years after cessation — through cyclical progestogen exposure. Combined (oestrogen plus progestogen) hormone replacement therapy in postmenopausal women eliminates the excess endometrial cancer risk of oestrogen-only HRT. Lynch syndrome carriers require annual endometrial biopsy or Pipelle sampling plus transvaginal ultrasound beginning at age 35 years, and should be counselled about risk-reducing hysterectomy and bilateral salpingo-oophorectomy after completion of childbearing, per NCCN Lynch Syndrome guidelines. Tamoxifen-treated breast cancer patients require annual gynaecological examination and immediate evaluation of any abnormal uterine bleeding.

Postmenopausal women — defined as having no menstrual period for 12 consecutive months — who experience any vaginal bleeding, however light or brief, must be evaluated promptly with transvaginal ultrasound and endometrial biopsy to exclude endometrial carcinoma. This is a medical rule without exception: there is no 'normal' amount of postmenopausal bleeding, and delaying investigation risks upstaging at diagnosis. Premenopausal women with any of the following symptoms should request gynaecological evaluation without delay: intermenstrual bleeding (bleeding between periods), postcoital bleeding (bleeding after intercourse), periods that are significantly heavier than usual, or any pelvic discharge that is blood-tinged or unexplained — particularly if associated with obesity, PCOS, nulliparity, diabetes, or a family history of Lynch syndrome-associated cancers. Women with Lynch syndrome must attend their annual endometrial surveillance schedule even in the absence of symptoms. Women currently taking tamoxifen for breast cancer who develop any vaginal bleeding or discharge require gynaecological evaluation. Women with a family history of endometrial cancer in a first-degree relative, or with known PTEN hamartoma tumour syndrome (Cowden syndrome), should discuss endometrial surveillance with their gynaecologist from age 35 years. Pelvic pain, back pain, or abdominal bloating not explained by menstrual cycle changes or benign conditions in perimenopausal women deserve evaluation rather than expectant management.

Stage I: 5-year survival approximately 90%. Stage II: approximately 70%. Stage III: approximately 40-50%. Stage IV: approximately 15-20%. Molecular subtype is powerfully prognostic: POLE-mutated tumours have near-100% survival regardless of stage, while TP53-aberrant (copy number high, mainly serous type) tumours have the worst prognosis at approximately 40-50% even at early stage. MSI-H tumours benefit markedly from pembrolizumab-based immunotherapy, with response rates exceeding 50% and durable remissions in some patients. The prognosis for Managing Uterine Cancer: Causes, Symptoms, Treatment Options varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.